clinical trial
NeuroSense shares update from ALS treatment trial
July 2, 2024Research and Development NeuroSense, Neurology, als, clinical trial
NeuroSense has announced new statistically significant results from the 12-month analysis of its PARADIGM phase 2b study which assessed PrimeC …
AskBio initiates phase 2 Parkinson’s trial recruitment
June 26, 2024Research and Development AskBio, Neurology, Parkinson's disease, clinical trial
Asklepios BioPharmaceutical (AskBio), a subsidiary of Bayer, has announced that it has initiated the recruitment for its phase 2 REGENERATE-PD …
Vertex shares results from phase 1/2 trial of type 1 diabetes treatment
June 24, 2024Research and Development Diabetes, Vertex pharmaceuticals, clinical trial, diabetes
Vertex Pharmaceuticals has announced new data from its phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated …
Gilead shares phase 3 results from HIV prevention trial
June 21, 2024Research and Development Gilead, HIV, Infections and infestations, clinical trial
Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE 1 trial, which assessed the …
Takeda shares data from phase 3 trial of CIPD treatment
June 20, 2024Research and Development CIDP, Hyqvia, Neurology, Takeda, clinical trial
Takeda has announced data from the phase 3 ADVANCE-CIDP 3 trial, which assessed the safety and efficacy of Hyqvia (Immune …
First patient dosed in Assembly Biosciences’ phase 1b trial for hepatitis B treatment
June 19, 2024Research and Development Assembly Biosciences, Hepatology, clinical trial, hepatitis
Assembly Biosciences has announced that the first participant has been dosed in its phase 1b trial of ABI-4334, the company’s …
Innate Pharma shares results from phase 1/2 trial for blood cancer treatment
June 17, 2024Research and Development Innate Pharma, Oncology, blood cancer, clinical trial
Innate Pharma has announced updated efficacy and safety results from the dose-escalation part of the phase 1/2 study with SAR443579/IPH6101 …
Cara Therapeutics shares data from part a of notalgia paresthetica trial
June 13, 2024Research and Development Cara Therapeutics, Neurology, clinical trial, notalgia paresthetica, pruritus
Cara Therapeutics has announced the outcome from the dose-finding Part A of the KOURAGE-1 study which assessed the efficacy and …
Tracon shares data from phase 2 trial for glioblastoma treatment
June 12, 2024Medical Communications Oncology, Tracon Pharmaceuticals, clinical tria, clinical trial, glioblastoma
Tracon Pharmaceuticals has announced the publication of its phase 2 clinical data for its DNA damage repair inhibitor drug candidate, …
Eli Lilly shares results for tirzepatide for MASH resolution
June 10, 2024Research and Development Eli Lilly, Hepatology, MASH, clinical trial, liver
Eli Lilly has announced results from the phase 2 SYNERGY-NASH study which assessed 190 patients, with or without type 2 …
AbbVie initiates phase 3 multiple myeloma trial
June 6, 2024Medical Communications ABBV-383, AbbVie, Oncology, clinical trial, multiple myeloma
AbbVie has announced that it has dosed the first patient in its phase 3 CERVINO trial, which aims to assess …
Sanofi shares phase 3 trial results for Sarclisa in multiple myeloma treatment
June 5, 2024Research and Development Oncology, Sanofi, Sarclisa, clinical trial, multiple myeloma
Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide …
Oryzon Genomics announces publication of phase 2a ALICE trial results
June 4, 2024Medical Communications AML, Oncology, Oryzon genomics, acute myeloid leukaemia, clinical trial
Oryzon Genomics has announced that the final results from its phase 2a ALICE study have been published online in The …
Gilead and Arcus announce results from colorectal cancer treatment trial
June 3, 2024Research and Development Arcus, Gilead, Oncology, clinical trial, colorectal cancer
Gilead Sciences and Arcus Biosciences have announced new data from cohort B of ARC-9, a phase 1b/2 study which aims …
Merck shares data from phase 3 trial of Keytruda for TNBC treatment
May 29, 2024Medical Communications Merck, Oncology, breast cancer, clinical trial, keytruda
Merck, known as MSD outside of the US and Canada, has announced results from the phase 3 KEYNOTE-522 trial, which …
Latest content
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader
